Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Delayed Function of Renal Transplant
Interventions: SANGUINATE, Normal Saline; Drug
Lead sponsor: Prolong Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 15 more

Conditions: Pre-eclampsia
Interventions: Placebo, RLX030; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dazucorilant 300 mg, Dazucorilant 150 mg, Placebo, Dazucorilant; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more

Conditions: Necrotizing Enterocolitis
Interventions: hydrocortisone, placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 0 Days to 6 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: ANCA-Associated Vasculitis
Interventions: Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo, Background Statin Therapy; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 134
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more

Conditions: Celiac Disease
Interventions: 4 dose levels of ALV003; Drug
Lead sponsor: Alvine Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Delayed Graft Function
Interventions: Furosemide, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Coronary Artery Disease (CAD)
Interventions: Evolocumab, Placebo, Statin therapy; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: Inclusion Body Myositis
Interventions: Arimoclomol, Placebo; Drug · Other
Lead sponsor: ZevraDenmark; Industry
Eligibility: 45 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more

Conditions: Septic Shock
Interventions: hydrocortisone, Normal Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Wound
Interventions: Autologous Fat Transfer; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Gainesville, Florida • Fort Sam Houston, Texas • Charlottesville, Virginia

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 34
States / cities: Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more

Conditions: Healthy
Interventions: Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acute Myeloid Leukemia
Interventions: 33A, placebo, azacitidine, decitabine; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 40
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 32 more

Conditions: ADHD
Interventions: KP415 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Zevra Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more

Conditions: Clostridium Difficile Infection
Interventions: Oral Vancomycin, Placebo; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Borderline Hypokalemia
Interventions: K+ supplement, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chordoma
Interventions: Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph; Other · Biological · Radiation + 1 more
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Evaluation of Dupilumab in Children With Uncontrolled Asthma

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease

Delayed Renal Allograft Function and Furosemide Treatment

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Milrinone in Congenital Diaphragmatic Hernia

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock

Autologous Fat Transfer for Scar Prevention and Remodeling

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Interaction Between ABT-335, Rosuvastatin and Warfarin

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

The Effects of Potassium on Glucose Metabolism in African Americans

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma